Skip to main content

Advertisement

SpringerLink
Log in

High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response

  • Oncology
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract

Objectives

To determine the acquisition delay after gadolinium-chelate injection that optimizes the prediction of the histological response during anthracycline-based neoadjuvant chemotherapy (NAC) for locally advanced high-grade soft-tissue sarcomas (STS).

Methods

Thirty patients (mean age 62 years) were included in this IRB-approved study. All patients received 5-6 cycles of NAC followed by surgery. A good response was defined as ≤ 10% viable cells on histological analysis of the surgical specimen. DCE-MRI was performed before treatment (MRI0) and after two cycles (MRI1). Images were obtained every 8 s. Change in contrast enhancement (CE) between MRI0 and MRI1 was calculated for each acquisition delay ‘t’ on the whole tumor volume. Area under the receiver-operating characteristics curves (AUROC) for change in CE was calculated at each acquisition delay, as well as the accuracy of the Choi criteria.

Results

There were 22 (73.3%) poor responders. Acquisition delay had a significant effect on change in CE and on the response status according to Choi (p = 0.0014 and 0.0270, respectively). The highest AUROC was obtained at t = 58 s (0.792) with an optimal threshold of a -30.5% decrease in CE. At t = 58 s, accuracy to predict a poor response was 82.8% above this threshold, while it was 72.4% and 70% with no objective response according to the Choi criteria and RECIST1.1, respectively.

Conclusion

Optimization of acquisition delay after injection to estimate change in CE improves the prediction of histological response. For STS undergoing NAC, a 60-s delay can be recommended with MRI.

Key points

• Accuracy of response criteria based on contrast enhancement, like the Choi criteria, is dependent on the acquisition delay after gadolinium-chelate injection.

• DCE-MRI helps determine the optimal acquisition delay after gadolinium-chelate injection for improving evaluation of tumor response.

• In soft tissue sarcoma, an acquisition delay at 60 s optimizes the evaluation of the response and accuracy of the Choi criteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

ADC:

Apparent diffusion coefficient

AUROC:

Area under the ROC curve

CE:

Contrast enhancement

CI95% :

95% confidence interval

DWI:

Diffusion-weighted imaging

EORTC:

European Organization for Research and Treatment of Cancer

FNCLCC:

Fédération Nationale des Centres de Lutte contre le Cancer

Good-HR:

Good histological responder

GRE:

Gradient-recalled echo

LD:

Longest diameter

MRI:

Magnetic resonance imaging

NAC:

Neoadjuvant chemotherapy

NPV:

Negative predictive value

OR:

Odds ratio

Poor-HR:

Poor histological responder

PPV:

Predictive positive value

RECIST:

Response evaluation criteria in solid tumors

Se:

Sensitivity

SI:

Signal intensity

SNR:

Signal-to-noise ratio

Sp:

Specificity

STS:

Soft-tissue sarcoma

TSE:

Turbo spin echo

References

  1. Issels RD, Lindner LH, Verweij J et al (2010) Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11:561–570. https://doi.org/10.1016/S1470-2045(10)70071-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Saponara M, Stacchiotti S, Casali PG, Gronchi A (2017) (Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. Eur J Cancer 70:1–11. https://doi.org/10.1016/j.ejca.2016.09.030

    Article  CAS  PubMed  Google Scholar 

  3. Pasquali S, Gronchi A (2017) Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol 9:415–429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gronchi A, Ferrari S, Quagliuolo V et al (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18:812–822. https://doi.org/10.1016/S1470-2045(17)30334-0

    Article  CAS  PubMed  Google Scholar 

  5. Wardelmann E, Haas RL, Bovée JV et al (2016) Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC–STBSG) recommendations for pathological examination and reporting. Eur J Cancer 53:84–95. https://doi.org/10.1016/j.ejca.2015.09.021

  6. Cousin S, Crombé A, Italiano A et al (2017) Clinical, radiological and genetic features associated with the histopathologic response to neoadjuvant chemotherapy (NAC) and outcomes in locally advanced soft tissue sarcoma (STS) patients. J Clin Oncol 35(15_suppl):11014

    Article  Google Scholar 

  7. Mo Z, Zhang T, Zhang F et al (2018) Feasibility and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure. Eur Radiol 28:1194–1203. https://doi.org/10.1007/s00330-017-5036-0

    Article  PubMed  Google Scholar 

  8. Pollack SM, Ingham M, Spraker MB, Schwartz GK (2018) Emerging targeted and immune-based therapies in sarcoma. J Clin Oncol 36:125–135. https://doi.org/10.1200/JCO.2017.75.1610

    Article  CAS  PubMed  Google Scholar 

  9. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  10. Benz MR, Czernin J, Eilber FC et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856–2863. https://doi.org/10.1158/1078-0432.CCR-08-2537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dudeck O, Zeile M, Hamm B et al (2008) Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 27:1109–1113. https://doi.org/10.1002/jmri.21358

    Article  PubMed  Google Scholar 

  12. van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC et al (2003) Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results. Eur Radiol 13:1849–1858. https://doi.org/10.1007/s00330-002-1785-4

  13. Meyer JM, Perlewitz KS, Ryan CW et al (2013) Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res 19:6902–6911. https://doi.org/10.1158/1078-0432.CCR-13-1594

    Article  CAS  PubMed  Google Scholar 

  14. Huang W, Beckett BR, Ryan CW et al (2016) Evaluation of soft tissue sarcoma response to preoperative chemoradiotherapy using dynamic contrast-enhanced magnetic resonance imaging. Tomography 2:308–316

    Article  PubMed  PubMed Central  Google Scholar 

  15. Soldatos T, Ahlawat S, Montgomery E, Chalian M, Jacobs MA, Fayad LM (2015) Multiparametric assessment of treatment response in high-grade soft-tissue sarcomas with anatomic and functional MR imaging sequences. Radiology 278:831–840

  16. Xia W, Yan Z, Gao X (2017) Volume fractions of DCE-MRI parameter as early predictor of histologic response in soft tissue sarcoma: A feasibility study. Eur J Radiol 95:228–235. https://doi.org/10.1016/j.ejrad.2017.08.021

    Article  PubMed  Google Scholar 

  17. Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447–456

    Article  PubMed  Google Scholar 

  18. Stacchiotti S, Verderio P, Messina A et al (2012) Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 118:5857–5866. https://doi.org/10.1002/cncr.27624

    Article  PubMed  Google Scholar 

  19. Trojani M, Contesso G, Coindre JM et al (1984) Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33:37–42

    Article  CAS  PubMed  Google Scholar 

  20. Perkins NJ, Schisterman EF (2006) The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 163:670–675. https://doi.org/10.1093/aje/kwj063

    Article  PubMed  Google Scholar 

  21. Taieb S, Saada-Bouzid E, Tresch E et al (1990) (2015) Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. Eur J Cancer 51:202–209. https://doi.org/10.1016/j.ejca.2014.11.008

  22. Hargreaves BA (2012) Rapid gradient-echo imaging. J Magn Reson Imaging 36:1300–1313. https://doi.org/10.1002/jmri.23742

  23. Zur Y, Wood ML, Neuringer LJ (1991) Spoiling of transverse magnetization in steady-state sequences. Magn Reson Med 21:251–263

    Article  CAS  PubMed  Google Scholar 

  24. Gruber L, Loizides A, Ostermann L, Glodny B, Plaikner M, Gruber H (2016) Does size reliably predict malignancy in soft tissue tumours? Eur Radiol 26:4640–4648

  25. Sagiyama K, Watanabe Y, Honda H et al (2017) Multiparametric voxel-based analyses of standardized uptake values and apparent diffusion coefficients of soft-tissue tumours with a positron emission tomography/magnetic resonance system: Preliminary results. Eur Radiol 27:5024–5033. https://doi.org/10.1007/s00330-017-4912-y

    Article  PubMed  Google Scholar 

  26. Liang J, Sammet S, Yang X, Jia G, Takayama Y, Knopp MV (2010) Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging. Invest Radiol 45:233–244

Download references

Funding

The authors state that this work has not received any funding.

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Institut Bergonie, Comprehensive Cancer Center, 229 cours de l’Argonne, F-33000, Bordeaux, France

    Amandine Crombé, Xavier Buy & Michèle Kind

  2. Modelisation in Oncology (MOnc) Team, INRIA Bordeaux-Sud-Ouest, CNRS UMR 5251 & Université de Bordeaux, F-33405, Talence, France

    Amandine Crombé

  3. University of Bordeaux, F-33000, Bordeaux, France

    Amandine Crombé, François Le Loarer & Antoine Italiano

  4. Department of Pathology, Institut Bergonie, F-33000, Bordeaux, France

    François Le Loarer

  5. Department of Radiology, Tenon Hospital, Sorbonne University, APHP, F-75020, Paris, France

    François Cornelis

  6. Department of Surgery, Institut Bergonie, F-33000, Bordeaux, France

    Eberhardt Stoeckle

  7. Department of Medical Oncology, Institut Bergonie, F-33000, Bordeaux, France

    Sophie Cousin & Antoine Italiano

Authors
  1. Amandine Crombé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. François Le Loarer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. François Cornelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eberhardt Stoeckle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xavier Buy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sophie Cousin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antoine Italiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michèle Kind
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amandine Crombé.

Ethics declarations

Guarantor

The scientific guarantor of this publication is Dr. Xavier Buy (interventional radiologist, head of the Department of Radiology of Institut Bergonié, comprehensive cancer center of Bordeaux, France, x.buy@bordeaux.unicancer.fr).

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Statistics and biometry

No complex statistical method was necessary for this paper. Statistical analysis was performed by A. Crombe, a PhD student in applied mathematics at the Institut de Mathématiques de Bordeaux (MOnc Team, INRIA Bordeaux Sud-Ouest CNRS UMR 5251).

Informed consent

Written informed consent was waived by the Institutional Review Board.

Ethical approval

Institutional Review Board approval was obtained.

Methodology

• retrospective

• diagnostic or prognostic study

• performed at one institution

Electronic supplementary material

ESM 1

(DOCX 28 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crombé, A., Le Loarer, F., Cornelis, F. et al. High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response. Eur Radiol 29, 545–555 (2019). https://doi.org/10.1007/s00330-018-5635-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-018-5635-4

Keywords

Search

Navigation